Mental and cognitive representations are believed to reside on low-dimensional, non-linear manifolds embedded within high-dimensional brain activity. Uncovering these manifolds is key to understanding individual differences in brain function, yet most existing machine learning methods either rely on population-level spatial alignment or assume data that is temporally structured, either because data is aligned among subjects or because event timings are known. We introduce a manifold learning framework that can capture subject-specific spatial variations across both structured and temporally unstructured neuroimaging data. On simulated data and two naturalistic fMRI datasets (Sherlock and Forrest Gump), our framework outperforms group-based baselines by recovering more accurate and individualized representations. We further show that the framework scales efficiently to large datasets and generalizes well to new subjects. To test this, we apply the framework to temporally unstructured resting-state fMRI data from individuals with schizophrenia and healthy controls. We further apply our method to a large resting-state fMRI dataset comprising individuals with schizophrenia and controls. In this setting, we demonstrate that the framework scales efficiently to large populations and generalizes robustly to unseen subjects. The learned subject-specific spatial maps our model finds reveal clinically relevant patterns, including increased activation in the basal ganglia, visual, auditory, and somatosensory regions, and decreased activation in the insula, inferior frontal gyrus, and angular gyrus. These findings suggest that our framework can uncover clinically relevant subject-specific brain activity patterns. Our approach thus provides a scalable and individualized framework for modeling brain activity, with applications in computational neuroscience and clinical research.

The research presents a machine learning (ML) classifier designed to differentiate between schizophrenia patients and healthy controls by utilising features extracted from electroencephalogram (EEG) data, specifically focusing on event-related potentials (ERPs) and certain demographic variables. The dataset comprises data from 81 participants, encompassing 32 healthy controls and 49 schizophrenia patients, all sourced from an online dataset. After preprocessing the dataset, our ML model achieved an accuracy of 99.930%. This performance outperforms earlier research, including those that used deep learning methods. Additionally, an analysis was conducted to assess individual features' contribution to improving classification accuracy. This involved systematically excluding specific features from the original dataset one at a time, and another technique involved an iterative process of removing features based on their entropy scores incrementally. The impact of these removals on model performance was evaluated to identify the most informative features.

Machine learning is employed in healthcare to draw approximate conclusions regarding human diseases and mental health problems. Compared to older traditional methods, it can help to analyze data more efficiently and produce better and more dependable results. Millions of people are affected by schizophrenia, which is a chronic mental disorder that can significantly impact their lives. Many machine learning algorithms have been developed to predict and prevent this disease, and they can potentially be implemented in the diagnosis of individuals who have it. This survey aims to review papers that have focused on the use of deep learning to detect and predict schizophrenia using EEG signals, functional magnetic resonance imaging (fMRI), and diffusion magnetic resonance imaging (dMRI). With our chosen search strategy, we assessed ten publications from 2019 to 2022. All studies achieved successful predictions of more than 80%. This review provides summaries of the studies and compares their notable aspects. In the field of artificial intelligence (AI) and machine learning (ML) for schizophrenia, significant advances have been made due to the availability of ML tools, and we are optimistic that this field will continue to grow.

Deep learning has been successfully applied to recognizing both natural images and medical images. However, there remains a gap in recognizing 3D neuroimaging data, especially for psychiatric diseases such as schizophrenia and depression that have no visible alteration in specific slices. In this study, we propose to process the 3D data by a 2+1D framework so that we can exploit the powerful deep 2D Convolutional Neural Network (CNN) networks pre-trained on the huge ImageNet dataset for 3D neuroimaging recognition. Specifically, 3D volumes of Magnetic Resonance Imaging (MRI) metrics (grey matter, white matter, and cerebrospinal fluid) are decomposed to 2D slices according to neighboring voxel positions and inputted to 2D CNN models pre-trained on the ImageNet to extract feature maps from three views (axial, coronal, and sagittal). Global pooling is applied to remove redundant information as the activation patterns are sparsely distributed over feature maps. Channel-wise and slice-wise convolutions are proposed to aggregate the contextual information in the third view dimension unprocessed by the 2D CNN model. Multi-metric and multi-view information are fused for final prediction. Our approach outperforms handcrafted feature-based machine learning, deep feature approach with a support vector machine (SVM) classifier and 3D CNN models trained from scratch with better cross-validation results on publicly available Northwestern University Schizophrenia Dataset and the results are replicated on another independent dataset.

For most of us, when we think of schizophrenia, our minds go back to the movie Sybil starring Sally Field and her multiple personalities. Whether Sybil had the disorder is debatable, but 1% of the world's population diagnosed with schizophrenia suffer from hallucinations, delusion, and cognitive deficits. "Schizophrenia is a devastating disease," said Robert Waterland, PhD, professor of pediatrics-nutrition at Baylor College of Medicine. "Although genetic and environmental components seem to be involved in the condition, current evidence only explains a small portion of cases, suggesting that other factors, such as epigenetic, also could be important." Waterland and his colleagues at the Baylor College of Medicine have now developed an innovative strategy that promises the ability for early diagnosis of schizophrenia.

Summary: Blood tests revealed specific epigenetic biomarkers for schizophrenia. Researchers applied machine learning to analyze the CoRSIVs region of the human genome to identify the schizophrenia biomarkers. Testing the model with an independent data set revealed the AI technology can detect schizophrenia with 80% accuracy. An innovative strategy that analyzes a region of the genome offers the possibility of early diagnosis of schizophrenia, reports a team led by researchers at Baylor College of Medicine. The strategy applied a machine learning algorithm called SPLS-DA to analyze specific regions of the human genome called CoRSIVs, hoping to reveal epigenetic markers for the condition.

Summary: Combining brain scans with AI technology, researchers were able to accurately predict the likelihood of a person developing schizophrenia in those with a family history of the psychiatric disorder. University of Alberta researchers have taken another step forward in developing an artificial intelligence tool to predict schizophrenia by analyzing brain scans. In recently published research, the tool was used to analyze functional magnetic resonance images of 57 healthy first-degree relatives (siblings or children) of schizophrenia patients. It accurately identified the 14 individuals who scored highest on a self-reported schizotypal personality trait scale. Schizophrenia, which affects 300,000 Canadians, can cause delusions, hallucinations, disorganized speech, trouble with thinking and lack of motivation, and is usually treated with a combination of drugs, psychotherapy and brain stimulation.

We demonstrate a hybrid machine learning method to classify schizophrenia patients and healthy controls, using functional magnetic resonance imaging (fMRI) and single nucleotide polymorphism (SNP) data. The method consists of four stages: (1) SNPs with the most discriminating information between the healthy controls and schizophrenia patients are selected to construct a support vector machine ensemble (SNP-SVME). The method was evaluated by a fully validated leave-one-out method using 40 subjects (20 patients and 20 controls). The classification accuracy was: 0.74 for SNP-SVME, 0.82 for Voxel-SVME, 0.83 for ICA-SVMC, and 0.87 for Combined SNP-fMRI. Experimental results show that better classification accuracy was achieved by combining genetic and fMRI data than using either alone, indicating that genetic and brain function representing different, but partially complementary aspects, of schizophrenia etiopathology.